AbbVie announced that the SKYRIZI® subcutaneous administration induction treatment plan has been approved by the US Food and Drug Administration to treat adult patients with moderately to severely active Crohn's disease.

Zhitongcaijing · 2d ago
AbbVie announced that the SKYRIZI® subcutaneous administration induction treatment plan has been approved by the US Food and Drug Administration to treat adult patients with moderately to severely active Crohn's disease.